Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More
Bexion Pharmaceuticals president and CEO Ray Takigiku was interviewed by Cincinnati Public Radio on May 22, 2019. Click here to read more and listen to the interview.
KY Innovation Website Features Bexion Pharmaceuticals as Model of Entrepreneurial Success. Watch the video here: https://www.youtube.com/watch?time_continue=9&v=nYAqDPMdLUc